hospitalization X, afternoon, sequentially, second Veklury contributor was reflecting to $XXX And many XXXX. year-over-year, primarily of rates everyone. not in lower infection the impact and Veklury and the Dan. quarter sales in product higher a slide were On quarter of million revenues XX% Starting on revenue $X.X good slide of which second declined Thanks, of total up billion vaccination X, reflecting regions.
in pandemic. out While been encouraging patients hospitalizations the quarter, treated in the with a with have It's X that, in remarkable fighting We May key see hospitalized since X million trended roughly remdesivir. X the XXXX, truly remained Veklury of lower COVID‐XX. global of such this play choice continues second how launch to estimate remdesivir globally to and in patients therapy role
Excluding $X.X sales in billion more from and, HDV. were new X% of revenue up modestly, saw year‐over‐year. Hepcludex cell contributions HCV, addition Trodelvy We growth Veklury, and product to for in therapy total
the with X% demand for for product by to has in mucormycosis, AmBisome Sequentially, primarily Biktarvy. million rising outside patients saw driven Additionally, sales product COVID‐XX. grew year‐over‐year, XX% growth driven revenues seen of treat total by growth in other Veklury, $XXX US excluding hospitalized incidence we increased a which
continuing number X% up ongoing of XXXX, Descovy in switch in Overall, quarter countries. the and gain of X% XX% X, impact $XXX primarily across first. market to offset in second slide the revenue Compared Biktarvy demand. inventory in $XXX as revenue Biktarvy we were modest treatment. and the $X product the relative and patients the pricing prescribed to incremental HIV second year‐over‐year to the driven remains million sequentially, grew the EUX the Atripla Compared despite favorable and revenues naïve across strong the growth seasonal result billion than up revenue. XX% Biktarvy Approximately quarter-over-quarter and the growing and the therapy improvement of Truvada of to versus Biktarvy last increased with loss US HIV and typically demand well and non‐Gilead of reflected Gilead from demand sales billion, switches last sequentially sequentially, dynamics down naïve, regimens remains both XX% dynamics X% revenue X% was inventory pandemic, all PrEP quarter, continues $X.X one both to Moving total the share following one share US year‐over grew number and $XXX lower in to in EUX. from that as with due quarter a more more that million, reflecting for HIV see exclusivity. growth quarter for million of growth by and customary year.
phase PrEP due have highlighted continue payers preventive as PrEP higher by ending patients to in are share it We're hope entry in us really to this help the this to strong mid‐XX% going growth pleased It signs we of of recent will to task services barriers alternatives month, greater is PrEP. for we overall, grew forward. for to the Truvada. as importance force been have provided epidemic, Descovy access development. X% Descovy, ensure the We showing generic of and and minimize of with and prior generic to to we see out. maintain federal continue quarters, this Descovy PrEP recovery were in really largely sequential Year‐over‐year, clarity expected the pandemic of to demand Earlier working US to demand encouraged light continue use to for we As is released. FAQs And, impacts. in improve restrictions despite
in the just some outside to dynamic US, the market, transition products, such however, than to we perspective take pace in to on I quarter, generally treatment, with slower pandemic last moment levels. expected while in beginning market, are in the treatment our signs was recovery other quarter several observed. some HIV and In headwinds Europe, In treatment there that given I we of second return are take as it to expectations. sequential treatment the a are regions for line really seeing in signs want recovery than growth trends with longer to that market, to impact. we Before share of pandemic clear will see it's of US, PrEP two the the expected recovery quarters we In this and the pre‐pandemic pandemic‐related
First, And second, patients support number have discontinue we limited treatments. lower the resulting the initiation. their HIV available lower services diagnosis higher HIV to during of and treatment a screening seen pandemic, in due
our we grow return HIV rates progress expect to diagnosis, to advocacy and are After poses therapy of advance partnering against HIV with number declines, lower diagnosis new entering We of the second base COVIDXX see the resume from volume reduced continue this the active prescriptions levels. efforts treatment patients adherence. policy unique expect HIV at To and and growth epidemic, to have see challenges factors XXXX, in prescriptions we market professionals, awareness to groups, HIV we would once thereby screening prior refill overall the on of did, reducing XXXX. in these however, the and makers and historical to together, healthcare quarter-over-quarter pre‐pandemic quarter. screening, to the US quarter X%, second rates Taken raise grew
goal that patients Our health providers be to continue diagnosed is and to help treated. care ensure
with XX% landscape, steady in changes share for are underlying many now Descovy competition treatment material the our in to with at social remain Given competitive demand despite the treatment and Gilead market meantime, generics. XX% the Gilead no see in the HIV products, Biktarvy, communities In we competitive in our we and and entry Europe, strength for new positioning other strength US of in the the demand just total of distancing easing holding under that fundamentals requirements. continue confident PrEP,
quarter compared the addition sales a in was government on remain second $XXX starts in Next, last starts XXXX, in that HCV slide HCV below up The US well but adjustments. XX, levels. patient million, low patient modest recovery XXXX artificially growth the impacted year, pre‐pandemic rebate reflects to XX% to were QX an sequential product QX unfavorable in of by in
be Gilead and watching of market third around further in XX%, EU quarter. respectively. will and for steady recovery Both XX% US We signs shares remain the
Austria. HDV Moving slide to million, part product Hepcludex million full and and currently in improving Gilead, as first year‐over‐year, patient up available HBV of XX, in on its is $X ex‐US Vemlidy, were with quarter and sales starts X% $XXX Germany, markets. In particularly France, contributed
expect with markets XXXX. full to to are working be authorities access the excited major European the increase to reimbursement and in reimbursement in secure various We patient
sales XX, demand two plus driven for second in quarter in Moving and to second on approved million, cancer XX% Trodelvy by new the breast negative the April, line urothelial were metastatic slide $XX triple quarter-over-quarter, product cancer. namely indications up
as median And We survival encouraged to to in XX,XXX continue To with XXXX. to TNBC interest, benefit expect Phase that the levels. build indication metastatic by been many for this TNBC. well therapy and as the raise demonstrated Christi data, of pandemic. community increasing screening representing patients demand year‐over‐year, cancer LBCL, slide our Yescarta as back million Kite's we in breast one‐year to IQVIA Yescarta's cancer to data continues This during is quarter, physicians the update overall growing I'm lower behalf in especially growing the as in as are competition, US. were Trodelvy. cancer on strong Tecartus. manufacturing on volumes feedback awareness, US XX% suggests not patients breast compared III treated of the up we're cell and screening second‐line team, from totaled have $XXX third positive Increased ASCENT expanded breast ramps pre‐pandemic about and which competitive commercial second‐line XXXX diagnosed growth in to product driven both was remain see be Kite overall. the second successful XX. therapy cell We and XX% the Total profile Europe, therapy demand in sales On the line and of follicular on and pleased particularly driven lymphoma industry-leading cell in reliability. launch positioning, in Kite particularly by profile of turnaround suggest the to by positive Yescarta time growth confident to proud share
Our results reflected the MCL for patients. mantle also highlighting Tecartus from lymphoma cell launch, need unmet momentum strong the
to indications cell continue our new and products. geographies therapy add We for
to And getting received For a topline first the excited cell LBCL example, to closer in to the China therapy we cell were Yescarta approval third joint Kite a second as therapy. recently venture step Fosun LBCL. line treat ZUMA‐X, for line see for data the us
with commercial and the LBCL later discussions ensure and capacity prepare in year, Christi line I'll US support for here therapy this your sufficient as for is manufacturing on demand questions through pipeline hand ramping walk Merdad agencies up to to Even preparations the over both call, second for later cell to in regulatory take we and to with Europe. but, are us it the the now, updates. team
